CN116601149A - 作为p2x3抑制剂的氨基喹唑啉衍生物 - Google Patents

作为p2x3抑制剂的氨基喹唑啉衍生物 Download PDF

Info

Publication number
CN116601149A
CN116601149A CN202180079588.2A CN202180079588A CN116601149A CN 116601149 A CN116601149 A CN 116601149A CN 202180079588 A CN202180079588 A CN 202180079588A CN 116601149 A CN116601149 A CN 116601149A
Authority
CN
China
Prior art keywords
fluorophenyl
methyl
alkyl
quinazolin
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180079588.2A
Other languages
English (en)
Chinese (zh)
Inventor
C·费奥莱里
P·布鲁诺
M·比亚杰蒂
D·皮齐拉尼
D·帕拉
P·龙奇
S·瓜里恩托
C·贝克-格伦
H·范德珀尔
K·L·赫斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of CN116601149A publication Critical patent/CN116601149A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180079588.2A 2020-11-27 2021-11-26 作为p2x3抑制剂的氨基喹唑啉衍生物 Pending CN116601149A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20210189 2020-11-27
EP20210189.5 2020-11-27
PCT/EP2021/083141 WO2022112490A1 (en) 2020-11-27 2021-11-26 Amino quinazoline derivatives as p2x3 inhibitors

Publications (1)

Publication Number Publication Date
CN116601149A true CN116601149A (zh) 2023-08-15

Family

ID=73642588

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180079588.2A Pending CN116601149A (zh) 2020-11-27 2021-11-26 作为p2x3抑制剂的氨基喹唑啉衍生物

Country Status (10)

Country Link
US (1) US20240025880A1 (https=)
EP (1) EP4251620B1 (https=)
JP (1) JP7844468B2 (https=)
KR (1) KR20230113309A (https=)
CN (1) CN116601149A (https=)
AU (1) AU2021388923A1 (https=)
CA (1) CA3196333A1 (https=)
ES (1) ES3026309T3 (https=)
MX (1) MX2023005803A (https=)
WO (1) WO2022112490A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR132737A1 (es) 2023-05-22 2025-07-23 Chiesi Farm Spa Proceso e intermedios para la preparación de un inhibidor p2x3

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009432A1 (en) * 2007-04-02 2011-01-13 Zhi-Liang Wei Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof
CN113891745A (zh) * 2019-05-31 2022-01-04 奇斯药制品公司 作为p2x3抑制剂的氨基喹唑啉衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2038264B1 (en) 2006-06-29 2016-10-26 F.Hoffmann-La Roche Ag Tetrazole-substituted arylamides
PT2139334E (pt) 2007-04-17 2013-10-02 Evotec Ag Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
CA2715835C (en) 2008-02-29 2017-03-21 Renovis, Inc. Amide compounds, compositions and uses thereof
JP5608655B2 (ja) 2008-09-18 2014-10-15 エヴォテック アーゲー Ｐ２ｘ３受容体活性のモジュレーター
JPWO2016084922A1 (ja) 2014-11-28 2017-09-07 塩野義製薬株式会社 １，２，４−トリアジン誘導体およびその医薬組成物
WO2016088838A1 (ja) 2014-12-04 2016-06-09 塩野義製薬株式会社 プリン誘導体およびその医薬組成物
EP3230281B1 (en) 2014-12-09 2021-05-26 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
DK3355889T3 (da) 2015-09-29 2023-05-15 Afferent Pharmaceuticals Inc Diaminopyrimidin-p2x3- og p2x2/3-receptormodulatorer til anvendelse i behandling af hoste

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009432A1 (en) * 2007-04-02 2011-01-13 Zhi-Liang Wei Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof
CN113891745A (zh) * 2019-05-31 2022-01-04 奇斯药制品公司 作为p2x3抑制剂的氨基喹唑啉衍生物
CN114269432A (zh) * 2019-05-31 2022-04-01 奇斯药制品公司 作为p2x3抑制剂的氨基喹唑啉衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GÁBOR SZÁNTÓ等: "New P2X3 receptor antagonists. Part 2: Identification and SAR of quinazolinones", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 26, no. 16, 6 July 2016 (2016-07-06), pages 3905 - 3912, XP029663839, DOI: 10.1016/j.bmcl.2016.07.013 *

Also Published As

Publication number Publication date
KR20230113309A (ko) 2023-07-28
JP7844468B2 (ja) 2026-04-13
EP4251620C0 (en) 2025-04-16
MX2023005803A (es) 2023-05-29
AU2021388923A1 (en) 2023-05-25
JP2023550840A (ja) 2023-12-05
WO2022112490A1 (en) 2022-06-02
EP4251620B1 (en) 2025-04-16
EP4251620A1 (en) 2023-10-04
US20240025880A1 (en) 2024-01-25
ES3026309T3 (en) 2025-06-11
AU2021388923A9 (en) 2024-02-08
CA3196333A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
CN113891745B (zh) 作为p2x3抑制剂的氨基喹唑啉衍生物
EP4251617B1 (en) (aza)quinoline 4-amines derivatives as p2x3 inhibitors
CN116745284A (zh) 作为p2x3抑制剂的酞嗪衍生物
CN116601149A (zh) 作为p2x3抑制剂的氨基喹唑啉衍生物
RU2821714C2 (ru) Производные аминохиназолина в качестве p2x3 ингибиторов
HK40089089A (zh) 作为p2x3抑制剂的氨基喹唑啉衍生物
RU2833037C2 (ru) Производные пиридопиримидинов в качестве ингибиторов p2x3
HK40106991A (zh) 作为p2x3抑制剂的氨基喹唑啉衍生物
HK40062196B (zh) 作为p2x3抑制剂的氨基喹唑啉衍生物
HK40057265A (en) Amino quinazoline derivatives as p2x3 inhibitors
HK40057265B (zh) 作为p2x3抑制剂的氨基喹唑啉衍生物
HK40062196A (en) Amino quinazoline derivatives as p2x3 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40089089

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination